Update on systemic treatment for newly diagnosed inflammatory breast cancer,Journal of Advanced Research

当前位置： X-MOL 学术 › J. Adv. Res. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Update on systemic treatment for newly diagnosed inflammatory breast cancer
Journal of Advanced Research ( IF 11.4 ) Pub Date : 2020-08-29 , DOI: 10.1016/j.jare.2020.08.014
Sudpreeda Chainitikun _{1,

2} , Sadia Saleem _{1,

2} , Bora Lim _{1,

2} , Vicente Valero _{1,

2} , Naoto T Ueno _{1,

2}

Affiliation

Background

Inflammatory breast cancer (IBC) is a rare and aggressive disease, accounting for 2–4% of new cases of breast cancer. Owing to its aggressive nature, IBC represent approximately 8–10% of breast cancer deaths. Management of IBC requires a multidisciplinary team for decision-making involving a composite of systemic treatment, surgery, and radiation, or “Trimodality Treatment.” Because of the rarity of the disease, systemic therapy of IBC traditionally has been extrapolated from non-IBC clinical trials.

Aim of Review

The purpose of this review is to provide an overview of the development of systemic treatment of IBC from the past to the present by focusing on IBC clinical trials, including chemotherapy and targeted therapies.

Key Scientific Concepts of Review

We discuss their effects on pathologic complete response (pCR) and survival outcomes, the predictive markers, and the adverse events of these therapies. Further, we summarized the current standard treatment stratified by molecular subtypes based on clinical data. Finally, we discuss the future trend of systemic therapy, including immunotherapy and ongoing IBC clinical trials.

中文翻译：

新诊断的炎性乳腺癌全身治疗的最新进展

背景

炎性乳腺癌 (IBC) 是一种罕见的侵袭性疾病，占乳腺癌新发病例的 2-4%。由于其侵袭性，IBC 约占乳腺癌死亡人数的 8-10%。 IBC 的管理需要一个多学科团队进行决策，涉及全身治疗、手术和放射的组合，或“三联治疗”。由于该疾病的罕见性，IBC 的全身治疗传统上是从非 IBC 临床试验中推断出来的。